Table 1 Baseline characteristics of all participants (n = 170). Data are summarized as mean ± SD or count (%)
Baricitinib dosage | 2 mg, 68 cases; 4 mg, 102 cases |
|---|---|
Age (years) | 61.0 ± 14.6 |
Sex | 143 (84.1%) women; 27 (25.9%) men |
Height (cm) | 156.1 ± 8.7 |
Weight (kg) | 56.5 ± 10.8 |
BMI (kg/m2) | 23.1 ± 3.59 |
Disease duration (years) | 15.2 ± 10.3 |
Steinbroker stage (1/2/3/4) | 30/60/27/53 |
Steinbroker class (1/2/3/4) | 48/99/20/3 |
Tender joint count (out of 28 joints) | 4.4 ± 4.6 |
Swollen joint count (out of 28 joints) | 2.7 ± 2.6 |
CRP (mg/dl) | 1.6 ± 2.6 |
Physician VAS | 40.2 ± 22.0 |
Patient VAS | 44.9 ± 25.7 |
CDAI | 15.5 ± 20.6 |
SDAI | 17.1 ± 24.1 |
MTX Dosage (mg/week) | 4.9 ± 4.7 |
PSL dosage (mg/day) | 2.7 ± 3.1 |
Rheumatoid factor positive rate | 72.9 |
Anti-CCP antibody positive rate (%) | 74.1 |
BIO use history: 1 drug | 44 |
BIO use history: 2 drugs | 43 |
BIO use history: 3 or more drugs | 45 |